The results from the reserches with Rimonabant pill And Tobacco Use research and the Rimonabant In Obesity research were presented here at a late-breaking clinical trials session at the 53rd annual scientific session of the American College of Cardiology.
Robert Anthenelli, MD, associate doctor of psychiatry at the University of Medicine and Cincinnati Veterans Affairs Medical Center in Ohio, and Jean-Pierre Despres, PhD, professor of medicine in Quebec City, Canada, presented the two researches' results.
Dr. Anthenelli claimed rimonabant medication has the potential to be the first "medicine to treat the two major risk factors for heart disease: smoking and obesity."
The research enrolled 790 smokers at 11 clinical trial sites in the U.S. The persons were randomized to rimonabant medication at a dose of 5 mg (n = 262) or 20 mg (n = 261) or to placebo. The average age of smokers was 45 years, and most had smoked about a pack a day for 10 to 25 years. The research lasted 11 weeks, and the smokers were allowed to smoke during the first 2weeks but were asked to abstain after that.
Participants who were smoke-free during the last 4 weeks of the research were considered treatment successes. Smoking cessation was verified by blood tests to measure cotinine and by measuring carbon monoxide levels in their breath.
About a 1/4 of the rimonabant consumers receiving the 20 mg dose stopped smoking in 10 weeks, which was "about twice the quit rate seen in the placebo arm," reported Dr. Anthenelli. That quit rate is slightly better than current smoking cessation helps such as nicotine gum or patches, doctor claimed.
No comments:
Post a Comment